Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for RYTM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 14.01M
March 31, 2026 57.05M
December 31, 2025 30.35M
September 30, 2025 -246.35M
June 30, 2025 54.04M
March 31, 2025 24.81M
December 31, 2024 21.16M
September 30, 2024 -90.82M
June 30, 2024 -8.562M
March 31, 2024 30.05M
December 31, 2023 22.64M
September 30, 2023 -94.96M
June 30, 2023 48.19M
March 31, 2023 18.46M
December 31, 2022 -40.78M
September 30, 2022 -39.70M
June 30, 2022 35.98M
March 31, 2022 72.52M
December 31, 2021 7.248M
September 30, 2021 62.78M
June 30, 2021 13.52M
March 31, 2021 -145.71M
Date Value
December 31, 2020 61.89M
September 30, 2020 34.91M
June 30, 2020 32.86M
March 31, 2020 28.87M
December 31, 2019 -139.13M
September 30, 2019 41.47M
June 30, 2019 46.14M
March 31, 2019 23.54M
December 31, 2018 12.28M
September 30, 2018 -136.47M
June 30, 2018 16.44M
March 31, 2018 20.61M
December 31, 2017 -111.45M
September 30, 2017 6.443M
June 30, 2017 2.983M
March 31, 2017 -8.019M
December 31, 2016
September 30, 2016 1.072M
June 30, 2016 -3.945M
March 31, 2016 -2.341M
December 31, 2015 -0.017M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. -8.529M
Alnylam Pharmaceuticals, Inc. -363.46M
BioMarin Pharmaceutical, Inc. -5.102B
Cytokinetics, Inc. -507.00M
Exelixis, Inc. 91.43M